| P2093 | author name string | Marcelo Pasquini | |
| | Stephen C Reingold | |
| | Jeffrey A Cohen | |
| | Neil J Scolding | |
| | International Conference on Cell-Based Therapies for Multiple Sclerosis | |
| | International Conference on Cell-Based Therapies for Multiple Sclerosis | |
| | International Conference on Cell-Based Therapies for Multiple Sclerosis | |
| P2860 | cites work | Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis | Q21245469 |
| | Human stem/progenitor cells from bone marrow promote neurogenesis of endogenous neural stem cells in the hippocampus of mice | Q24534272 |
| | Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells | Q24632072 |
| | Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing | Q24632520 |
| | Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine | Q24632756 |
| | Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT | Q24685958 |
| | Is it time to target no evident disease activity (NEDA) in multiple sclerosis? | Q26801550 |
| | Cell fusion in the brain: two cells forward, one cell back. | Q27691973 |
| | Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement | Q27861120 |
| | Adult rat and human bone marrow stromal cells differentiate into neurons | Q28142919 |
| | Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats | Q28209989 |
| | Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects | Q28264862 |
| | World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects | Q28300546 |
| | Transplantation of an acutely isolated bone marrow fraction repairs demyelinated adult rat spinal cord axons | Q28367760 |
| | Mesenchymal stem cells in health and disease | Q29614296 |
| | Mesenchymal and haematopoietic stem cells form a unique bone marrow niche | Q29616602 |
| | Somatic coding mutations in human induced pluripotent stem cells | Q29616798 |
| | Mesenchymal stem cells reside in virtually all post-natal organs and tissues | Q29617740 |
| | Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6 | Q29620590 |
| | Neonatal chimerization with human glial progenitor cells can both remyelinate and rescue the otherwise lethally hypomyelinated shiverer mouse | Q30514192 |
| | Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party | Q33395411 |
| | Actin cytoskeletal disruption following cryopreservation alters the biodistribution of human mesenchymal stromal cells in vivo | Q33949125 |
| | Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis | Q34109903 |
| | Characterization of in vitro expanded bone marrow-derived mesenchymal stem cells from patients with multiple sclerosis | Q34120467 |
| | Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study | Q34132522 |
| | Fetal and adult human oligodendrocyte progenitor cell isolates myelinate the congenitally dysmyelinated brain | Q34287449 |
| | A randomized trial of mesenchymal stem cells in multiple system atrophy. | Q34290126 |
| | Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic | Q34345195 |
| | A regenerative approach to the treatment of multiple sclerosis | Q34376469 |
| | Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. | Q34433743 |
| | Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials | Q34469147 |
| | Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo | Q34472745 |
| | Extensive fusion of haematopoietic cells with Purkinje neurons in response to chronic inflammation | Q34503325 |
| | Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience | Q59389207 |
| | Remyelination of CNS axons by Schwann cells transplanted from the sciatic nerve | Q67551674 |
| | FDA should stand firm on stem-cell treatments | Q74207390 |
| | Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates | Q78654754 |
| | Bone marrow transdifferentiation in brain after transplantation: a retrospective study | Q80035903 |
| | Normal bone marrow hematopoietic stem cell reserves and normal stromal cell function support the use of autologous stem cell transplantation in patients with multiple sclerosis | Q81311474 |
| | Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: implication for assessment of disease activity and treatment | Q81475298 |
| | Cell therapy medical tourism: time for action | Q82439275 |
| | Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis | Q83661349 |
| | Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis | Q83712580 |
| | Mitochondria to the rescue | Q84074088 |
| | Autologous hematopoietic stem cell transplantation for multiple sclerosis--if confused or hesitant, remember: 'treat with standard immune suppressive drugs and if no inflammation, no response' | Q84198425 |
| | Vision Loss after Intravitreal Injection of Autologous "Stem Cells" for AMD. | Q34553334 |
| | Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis | Q34564111 |
| | Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. | Q34600820 |
| | Multiple sclerosis: an immune or neurodegenerative disorder? | Q34786872 |
| | Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study | Q34934840 |
| | Endogenous tissue plasminogen activator mediates bone marrow stromal cell-induced neurite remodeling after stroke in mice | Q34978504 |
| | Medical innovation versus stem cell tourism | Q34989100 |
| | A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview | Q35181841 |
| | Adult stem cells for tissue repair - a new therapeutic concept? | Q35194623 |
| | Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation | Q35665181 |
| | The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail? | Q35671001 |
| | Comparative analysis of human mesenchymal stem cells from bone marrow and adipose tissue under xeno-free conditions for cell therapy | Q35677088 |
| | Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study | Q35757641 |
| | Adult stem cells--reprogramming neurological repair? | Q35832764 |
| | Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis | Q35846504 |
| | Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study | Q35882830 |
| | Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial. | Q35909839 |
| | CD140a identifies a population of highly myelinogenic, migration-competent and efficiently engrafting human oligodendrocyte progenitor cells | Q36002391 |
| | Repeat infusion of autologous bone marrow cells in multiple sclerosis: protocol for a phase I extension study (SIAMMS-II). | Q36053680 |
| | A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper | Q36075481 |
| | Assessment of bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS): study protocol for a randomised controlled trial | Q36163721 |
| | Hepatocyte growth factor mediates mesenchymal stem cell–induced recovery in multiple sclerosis models. | Q36188460 |
| | Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. | Q36402704 |
| | Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis | Q36484443 |
| | Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis | Q36484448 |
| | Cortical remyelination: a new target for repair therapies in multiple sclerosis. | Q36504051 |
| | Glial progenitor cell-based treatment and modeling of neurological disease | Q36544289 |
| | Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. | Q36793938 |
| | Neurogenesis in the chronic lesions of multiple sclerosis | Q36851475 |
| | Characterization of autologous mesenchymal stem cell-derived neural progenitors as a feasible source of stem cells for central nervous system applications in multiple sclerosis | Q36861620 |
| | Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines | Q37017086 |
| | Remyelination of the spinal cord following intravenous delivery of bone marrow cells | Q37020042 |
| | Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis | Q37124529 |
| | Autologous haematopoietic stem-cell transplantation in multiple sclerosis | Q37195389 |
| | Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. | Q37253314 |
| | New ISSCR guidelines underscore major principles for responsible translational stem cell research | Q37337489 |
| | Human Mesenchymal Stem Cells Impact Th17 and Th1 Responses Through a Prostaglandin E2 and Myeloid-Dependent Mechanism | Q37350687 |
| | Long-term evolution of multiple sclerosis disability in the treatment era. | Q37409279 |
| | Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation | Q37552052 |
| | T cell repertoire following autologous stem cell transplantation for multiple sclerosis | Q37602168 |
| | High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report | Q37603718 |
| | The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group | Q37677911 |
| | Human bone marrow and adipose tissue mesenchymal stem cells: a user's guide | Q37756932 |
| | Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis? | Q37769909 |
| | Resetting autoimmunity in the nervous system: The role of hematopoietic stem cell transplantation. | Q37820918 |
| | The therapeutic effect of mesenchymal stem cell transplantation in experimental autoimmune encephalomyelitis is mediated by peripheral and central mechanisms | Q37978701 |
| | Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. | Q37999098 |
| | Functional heterogeneity of mesenchymal stem cells: implications for cell therapy | Q38003340 |
| | Mesenchymal stem/stromal cells as a pharmacological and therapeutic approach to accelerate angiogenesis | Q38193251 |
| | Concise review: optimizing expansion of bone marrow mesenchymal stem/stromal cells for clinical applications | Q38200506 |
| | Patient-Funded Trials: Opportunity or Liability? | Q38562564 |
| | Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis | Q38734508 |
| | Pushing Forward: Remyelination as the New Frontier in CNS Diseases | Q38768775 |
| | Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation | Q38858092 |
| | Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis | Q38939585 |
| | Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial | Q38946774 |
| | Mesenchymal stem cells (MSC) derived from mice with experimental autoimmune encephalomyelitis (EAE) suppress EAE and have similar biological properties with MSC from healthy donors | Q39102182 |
| | Copy number variation and selection during reprogramming to pluripotency | Q39582693 |
| | Freedom from disease activity in multiple sclerosis | Q39876366 |
| | Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: an open label study | Q40271549 |
| | Immune-modifying agents do not impair the survival, migration or proliferation of oligodendrocyte progenitors (CG-4) in vitro | Q40640875 |
| | Cryopreserved Mesenchymal Stromal Cells Are Susceptible to T-Cell Mediated Apoptosis Which Is Partly Rescued by IFNγ Licensing. | Q41046577 |
| | Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study. | Q41310202 |
| | Autologous hematopoietic SCT normalizes miR-16, -155 and -142-3p expression in multiple sclerosis patients | Q41715953 |
| | Survival and Functionality of Human Induced Pluripotent Stem Cell-Derived Oligodendrocytes in a Nonhuman Primate Model for Multiple Sclerosis. | Q42708770 |
| | Adult human mesenchymal cells proliferate and migrate in response to chemokines expressed in demyelination | Q42735915 |
| | Human mesenchymal stem cells infiltrate the spinal cord, reduce demyelination, and localize to white matter lesions in experimental autoimmune encephalomyelitis. | Q43578851 |
| | The potential of human umbilical cord-derived mesenchymal stem cells as a novel cellular therapy for multiple sclerosis | Q44239818 |
| | Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. | Q44475978 |
| | Possible induction of acute disseminated encephalomyelitis (ADEM)-like demyelinating illness by intrathecal mesenchymal stem cell injection. | Q44756601 |
| | Gliosis and brain remodeling after treatment of stroke in rats with marrow stromal cells | Q45148313 |
| | Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study | Q45869701 |
| | Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry | Q46070761 |
| | Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation | Q46226618 |
| | Safety and feasibility of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis. | Q47586113 |
| | Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor | Q47590532 |
| | Cell therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases | Q47619959 |
| | Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician's and patient's perspectives | Q48048274 |
| | Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity | Q48112332 |
| | The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. | Q48183752 |
| | Induction of neurotrophin expression via human adult mesenchymal stem cells: implication for cell therapy in neurodegenerative diseases | Q48201557 |
| | Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis. | Q48368793 |
| | Mesenchymal stem cell-secreted superoxide dismutase promotes cerebellar neuronal survival | Q48371412 |
| | Purkinje cell fusion and binucleate heterokaryon formation in multiple sclerosis cerebellum | Q48378074 |
| | T cells become licensed in the lung to enter the central nervous system | Q48401917 |
| | Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort | Q48403390 |
| | Bone marrow stromal cells reduce axonal loss in experimental autoimmune encephalomyelitis mice | Q48497239 |
| | Glioproliferative Lesion of the Spinal Cord as a Complication of "Stem-Cell Tourism". | Q48662262 |
| | Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial | Q48682192 |
| | Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis | Q48704224 |
| | NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs. | Q48721170 |
| | Intravenous autologous bone marrow mononuclear cells for ischemic stroke | Q49015926 |
| | [Transplantation of mesenchymal stem cells in multiple sclerosis]. | Q50526194 |
| | Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. | Q52967863 |
| | Haematopoietic stem cell transplants should be a second-line therapy for highly active MS - NO. | Q53063105 |
| | Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. | Q53171235 |
| | Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. | Q53352599 |
| | Bone marrow mesenchymal stromal cells isolated from multiple sclerosis patients have distinct gene expression profile and decreased suppressive function compared with healthy counterparts. | Q54565698 |
| | Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis | Q57041496 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hematopoietic stem cell transplantation | Q1128050 |
| | multiple sclerosis | Q8277 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 2776-2796 | |
| P577 | publication date | 2017-11-01 | |
| P1433 | published in | Brain | Q897386 |
| P1476 | title | Cell-based therapeutic strategies for multiple sclerosis | |
| P478 | volume | 140 | |